cyrilzakka/clinical-trials huggingface dataset:
Induction of Labor by Oral Misoprostol Solution

AIM: To evaluate effectiveness and safety of titrated oral misoprostol solution (OMS) in comparison with static-dose oral misoprostol solution for induction of labor at term.

Women with singleton live pregnancy at term without any complications who were admitted in labor room for induction of labor were enrolled.

Study involves allocation of selected women in two groups randomly and use of either titrated or static oral misoprostol dose regimen to induce labor. Possible benefits included rapid induction of labor with oral drug regimen which is easier to comply as compared to vaginal regimens. Women were at risk of all the complications associated with induction of labor like labor abnormalities, risk of cesarean section, non reassuring fetal status.

This comparative randomized study was conducted in the Department of Obstetrics and Gynecology, Christian medical college and hospital, Ludhiana for a period of one year beginning from 1st December, 2017 to 30th November, 2018. The study group comprised of all antenatal women admitted in labor room at term for induction of labor. Informed consent was taken for all selected women. Women were subjected to detailed history taking, a complete physical examination including per vaginum examination (to calculate modified bishop's score and to rule out cephalopelvic disproportion), investigations and a NST. Gestational age was established by the first date of the last menstrual period and confirmed by first trimester ultrasound. Presentation was confirmed by palpation and third trimester ultrasound.

Women after randomization were allocated into two groups. The first group (A) was induced with hourly titrated oral misoprostol regimen and the second group (B) received two hourly static oral misoprostol regimen. Once labor had started, vital signs were closely monitored every 2 hours; fetal heart rate (FHR) and uterine activity every 15 minutes during first stage of labor. Per vaginum examination was done 4-hourly or as indicated.

Primary and secondary outcome measures were noted and analyzed to compare safety and efficacy of titrated and oral misoprstol solution.

Eligibility Criteria:
Inclusion Criteria:

1. Singleton live pregnancy;
2. ≥37 weeks gestation;
3. Cephalic presentation;
4. Reassuring fetal heart rate;
5. Modified Bishop'score

Exclusion Criteria:

1. Hypersensitivity to misoprostol;
2. Uterine scar due to previous cesarean section or other uterine surgery;
3. Grand multipara;
4. Multiple gestations;
5. High risk pregnanacies • preeeclampsia with severe features • significant maternal cardiac,renal, liver disease
6. Any contraindication to induction and vaginal delivery e.g. cephalopelvic disproportion, malpresentation, fetal compromise and ante partum hemorrhage
7. Intrauterine fetal demise
Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

This study evaluates the effect of cumulative dose administration of albuterol sulfate inhalation aerosol delivered with valved holding chamber and facemask. This is a four week study in birth to 23 month old subjects who are experiencing acute wheezing due to obstructive airways disease.


Eligibility Criteria:
Inclusion criteria:

* Must be an outpatient.
* Age at second visit must be birth to \<24 months old.
* Parent/guardian who is willing to sign, or has signed, an informed consent.
* Must have acute wheezing consistent with reversible obstructive airway disease.
* Must have an asthma symptoms score between 4-9 based on the TAL score (Modified Tal Asthma Symptoms Score measured by the study site) at Screening (Visit 1) while the subject is breathing room air.

Exclusion criteria:

* History of life-threatening asthma or wheezing that requires admission to an intensive care unit for treatment within 3 months prior to Screening, or he/she has been treated in the emergency room and admitted to the hospital for airways obstruction on two or more occasions within 3 months prior to Screening, or there is a history of intubation for respiratory distress due to airways obstruction.
* Has impending respiratory failure.
* Taken medications such as acute/chronic systemic corticosteroids, CNS stimulants, investigational medications, theophylline or aminophylline, anti-arrhythmic within a certain time period prior to the study.
* Having the following signs or symptoms: 1)present with fever (rectal temperature \>100.5 ºF or tympanic temperature \>101.5ºF); 2) present with known pulmonary (lung) and/or cardiac (heart) congenital malformations; 3) have an underlying chronic disease (respiratory (Chronic pulmonary disease includes congenital anomalies, bronchopulmonary dysplasia, and cystic fibrosis), cardiac, renal, or liver insufficiency, immunodeficiency, encephalopathy); 4) known or suspected foreign body aspiration; 5) their Modified Tal Asthma Symptoms Score is 10; 6) their weight is below a certain limit for the average for their age; 8) they were born before 34 weeks' gestation. 9) Laboratory tests for serum potassium and blood glucose within the following limits (potassium between 3.0-5.8 mEq/L and glucose between 45-140mg/dL).
Mechanism of Mindfulness Based Online Intervention in Reducing Emotional Distress: Daily Dairy Research

This study hopes to:

1. explore whether three weeks of MIED could promote experiential avoidance.
2. explore experiential avoidance could be a mediation of outcomes of MIED.

Experiential avoidance refers to individuals resisting experiences or trying to eliminate certain experiences (such as emotions, thoughts, physical feelings, memory and behavioral tendencies, etc.), and trying to adopt corresponding strategies to change these experiences and the situations in which the experiences are generated (Hayes, Wilson, Gifford, Follette, \& Strosahl, 1996). Experiential avoidance has been proved to be a maintenance factor for many psychological disorders (Boelen \& Reijntjes, 2008), and trying to hide or suppress unpleasant thoughts, feelings and physical feelings will increase the frequency and pain of these same experiences (Gross,1998; Gross,2002; Sloan, 2004; Wegner, 1994). According to some reviews, experiential avoidance is one of the beneficial effects of mindfulness (Brown, Bravo, Roos, \& Pearson, 2015; Shapiro et al., 2006). However, no study has examined experiential avoidance as mediator in mindfulness intervention whether in the between-subject or in within-subject level . Therefore, this study uses daily diary research explore the role of experiential avoidance as the effective mechanism of mindfulness intervention.

Eligibility Criteria:
Inclusion Criteria:

* Subjects with scores greater than 21 on the Kessler Psychological Distress Scale.

Exclusion Criteria:

* Subjects who could not access the Internet;
* Subjects with insufficient Chinese ability;
* Subjects who have participated in mindfulness based projects for more than 6 weeks before, and / or the current frequency of meditation practice is more than once a week;
* Patients with schizophrenia or psychotic affective disorder, current organic mental disorder, substance abuse disorder and generalized developmental disorder;
* Subjects at risk of suicide.
Viability Imaging in Volumetric Angiography (VIVA 1)

The primary objective of this study is twofold:

1. To define inter-reader variability of myocardial viability imaging within the first pass and delayed enhancement cardiac CT perfusion imaging
2. To evaluate DE CT image quality using a consensus DECT protocol

The presence of myocardial scar using radionuclide or magnetic resonance imaging techniques indicates myocardial segments with a reduced likelihood of functional recovery following myocardial revascularization. Preliminary evidence suggests that multi-detector CT (MDCT) angiography also can detect irreversible myocardial scarring through the detection of regions of delayed hyperenhancement (DE) of the myocardium.1-4 However, existing studies have been performed in single centers, and the reproducibility, and impact of this modality on recovery of myocardial function is unknown. In this study, the investigators propose a single-center trial using a standardized MDCT DE protocol among patients scheduled for clinical cardiac CT with planned reoperative surgical. The primary endpoint will be characteristics of DE imaging of the myocardium including its inter-reader variability and factors associated with image quality. These findings will further our understanding of the role of DE MDCT for the detection of myocardial viability.

Eligibility Criteria:
Inclusion Criteria:

* Eligible patients will be adults, ages 18 and above with:

  1. Known CAD with prior MI based upon clinical history or electrocardiographic criteria
  2. Planned redo-surgical myocardial revascularization
  3. Referred for CT (and eligible) for pre-op substernal mapping/coronary artery evaluation

Exclusion Criteria:

1. Inability to provide informed consent
2. Allergy to iodinated contrast media (unless pre-medicated with medical prophylaxis)
3. Chronic kidney disease manifested by a serum creatinine \>1.5 mg/dL, an estimated creatinine clearance \<50 ml/kg/min or on dialysis
4. Currently reporting or evaluated in NYHA class IV heart failure
Effect of Position Change on Pain, Comfort and Vascular Complications After Coronary Angiography

Today, complementary and alternative treatments are frequently used to maintain health and well-being, reduce symptoms of diseases, and provide relaxation. Nurses contribute to the healing process by using pharmacological and nonpharmacological methods. Pharmacological methods cause nausea, vomiting, respiratory depression, gastrointestinal and urinary system complications in individuals. Therefore, nonpharmacological methods without side effects are gaining importance. Nonpharmacological methods are easy and simple nursing interventions that do not have side effects, are cost-effective, can be easily taught to the patient, reduce pain and anxiety. They can also be used in addition to pharmacological methods and are preferred in patients who do not take medication or are unwilling to take medication. Providing a safe position without vascular complications and back pain after the procedure is very important for both the patient and the nurse who cares for the patient. Existing studies on post-intervention position changes have reported low incidences of bleeding and back pain, resulting in higher levels of patient comfort and satisfaction. These studies evaluated different angles of elevating the head of the bed and recommended further studies to evaluate the possibility of shifting patients to other positions after transfemoral cardiac interventions.

Therefore, the aim of this study was to investigate the effect of position change after coronary angiography on pain, comfort and vascular complications.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years of age

  * Agree to participate in the study
  * Not undergoing emergency coronary angiography
  * Not consuming coffee or hypnotic drugs at least 12 hours ago
  * No history of chronic pain (e.g. arthritis)
  * Not addicted to alcohol or drugs
  * No psychological problems (such as depression, anxiety disorder)
  * Not using anxiolytics

Exclusion Criteria:

* • Not willing to participate in the study

  * Developing delirium during the follow-up period
  * Developing complications after coronary angiography (such as bleeding etc.)
  * Arrhythmia
  * Hemodynamic instability
  * Hereditary bleeding disorders
  * Platelet count less than 100,000/mm3
  * Abnormal coagulation parameters (high INR and/or aPTT)
  * History of percutaneous coronary intervention (PCI)
  * Multiple or bilateral punctures in the femoral artery
  * Presence of hematoma on arrival after the procedure
  * Radial access
  * Bleeding at the access site or at the access dressing site
  * Body mass index (BMI) ≥ 35 kg/m2
  * Back pain before treatment
  * Patients with spinal cord disease
  * Patients with vertebral disc disease
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas

Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven high grae glioma with central pathology review at DHMC
* Age 18 equal to or greater than 18 years
* Karnofsky performance greater or equal to 60%
* Patients must have received radiation therapy and chemotherapy but should not have received any anti-angiogenesis therapy.

Exclusion Criteria:

* Any patient who requires urgent surgical resection of MRI abnormality would not be eligible
* Pregnant women are not eligible
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg


Eligibility Criteria:
Inclusion Criteria:

* The subject has given written informed consent prior to any study-related procedures
* The subject is male or female and is over 18 years of age
* The subject must have had documentation supporting the diagnosis of acromegaly, based on elevated IGF-1 and/or GH levels
* The subject has been receiving octreotide LAR (10 or 20 mg) treatment for at least six months and is biochemically controlled. Control is defined as normal (age and sex adjusted) IGF 1 levels for two consecutive measurements (at least two months apart) preceding study entry
* If the subject is receiving dopamine agonist therapy, treatment should be stable for at least four months, and no change in their dopamine-agonist medication is expected during the entire study period

Exclusion Criteria:

* The subject has received radiation therapy to the pituitary gland before study entry
* The subject has a history of hypersensitivity to lanreotide or drugs with a similar chemical structure
* The subject has received a growth hormone receptor antagonist (pegvisomant) therapy within three months before study entry
* The subject has undergone treatment with any other investigational drug in the 30 days before study entry or is scheduled to receive an investigational drug, other than lanreotide 120 mg, during the course of the study
* The subject has received any unlicensed drug within the 30 days prior to the baseline visit or is scheduled to receive an unlicensed drug during the course of the study
Effect of Core Exercise on ADL in Hemodialysis

Finding the effect of core stability exercises with breathing exercises on Activities of daily living (ADLs), fatigue level and balance in maintenance hemodialysis patients.

Sixty patients will be randomly assigned into two equal groups, the experimental (EX) group and the control group (CON). The participants' age will be 50-65 years and undergo hemodialysis. The Ex-group will attend three sessions/week of core stability exercise training (CSE) combined with Deep Breathing (25:30-min) for 8 weeks, the CON will attend 3 sessions/week of Deep Breathing (15-min) for 8 weeks. All the patients received only routine hemodialysis department care.

Eligibility Criteria:
Inclusion Criteria:

* Adults ranging from 55- 70 years old of both genders.
* Diagnosed as maintenance hemodialysis for at least 6 months or more.
* Free from mental illness, neuromuscular disorders, and serious lung problems and able to implement the interventional exercise.

Exclusion Criteria:

* Obesity (BMI ≥ 30 kg/m2)
* Orthopeadics or neurological problems that interferes with training.
* History of pulmonary problems (COPD, pneumonia)
* History of Myocardial infarction and/or cardiothoracic surgery
* Unstable medical status
* Dementia that interferes with the ability to follow instructions.
* History Chronic Fatigue Syndrome (CFS).
Establish and Apply the Evaluation System of Ultrasonic Integrated Technology for Prevention and Treatment of Acute Kidney Injury

Establish an integrated evaluation system of ultrasound technology for the prognosis of acute kidney injury, and in order to achieve non-invasive, reliable early diagnosis "gold standard". Set up collabration with the expert in National Cheng Kung University Medical Center of Taiwan who did a lot of excellent work in basic research of prevention the progression of acut kidney injury. Study the experience about prevention progression of kidney disease in clinical and basic field. Establish cooperation with the professional in Hong Kong University of Science and Technology. To set up the system of natural products research and assess the Astragalus medicinal value.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must satisfy the following criteria to be enrolled in the study:

  1. Clinical diagnosis of acute or chronic kidney injury
  2. Male or female, aged 18-80 years old
  3. signed informed consent
  4. Patients can breathe in, breathe out and hold their breathe with ease, communication without difficulty.

Exclusion Criteria:

* Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Refuse to sign informed consent
  2. allergy to micro bubble hexafluoride drug
  3. Patients with cardiopulmonary insufficiency, pleural effusion, pulmonary infections
  4. Patients with asthma, chronic bronchitis
  5. Patients with pregnancy
  6. Patients can't cooperate or have a difficulty in breathing in, breathing out or holding their breathe
  7. Patients beening diagnosed with End-stage kidney disease.
The Effect of Supplementation with Curcuminoids for the Improvement of Musculoskeletal Conditions in Sedentary Adults

The aim of this study is to evaluate the effect of a supplementation with curcuminoids, called Cal LX, prior to physical exercise, on the improvement of musculoskeletal conditions in sedentary people, which would lead to more physical exercise regularly.


Eligibility Criteria:
Inclusion Criteria:

* To be over 25 years old
* To have not exercised systematically during the last 3 months, or do not do physical exercise daily for more than 25 minutes per day for a maximum of 3 days per week
* Sitting for at least 4 hours continuously
* Type 2 diabetes patients.

Exclusion Criteria:

* To have a history or diagnoses of cardiopulmonary, osteoarticular, type 1 diabetes or autoimmune disorders
* Pregnancy
* Smokers.
Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial that will be carried out in Mexico. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral hemorrhage.

Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great amount of disability, economic and social burden. This is particularly true in developing countries where it accounts for between 20% and 50% of all strokes. Pharmacological and surgical interventions have been attempted to diminish the mortality and disability derived from ICH, with unsuccessful results. Recently the use of Fluoxetine in addition to physical rehabilitation has been proven useful to improve motor recovery from cerebral infarct. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral hemorrhage.

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial. This trial will recruit 86 patients with intracerebral hemorrhage of both sexes, ages \>18 years, from four Mexican hospitals. The patients will receive either 20mg of fluoxetine or a placebo once daily for 90 days. The primary outcome is the mean change in Fugl-Meyer Motor Scale score between inclusion (day 0) and day 90. The secondary outcomes will be changes in Barthel Index, Modified Rankin scale and National Institutes of Health (NIH) Stroke Scale. The outcomes will be measured at day 45±7days and at day 90, for a total of four visits with each subject (at screening and at 0, 45 and 90days).

Eligibility Criteria:
Inclusion Criteria:

* Patients who had an acute intracerebral hemorrhage within the past 10 days causing hemiparesis or hemiplegia
* Fugl-Meyer motor scale (FMMS) scores of 55 or less
* Written informed consent for participation in the trial

Exclusion Criteria:

* Severe post-stroke disability (National Institutes of Health stroke scale \[NIHSS\] score \>20)
* Premorbid disability, evidenced by residual motor deficit from a previous stroke
* Comprehension deficit or severe aphasia
* Previous diagnosis of depression or one of the following:

  * Hospital Anxiety and Depression Scale score ≥11 points
  * Taking antidepressant drugs two weeks before inclusion
* Taking neuroleptic drugs or benzodiazepines two weeks before inclusion
* Other major diseases with life expectancy less than 3 months.